Targeting stem cells by radiation: From the biological angle to clinical aspects
Alexis Vallard, Sophie Espenel, Jean-Baptiste Guy, Peng Diao, Yaoxiong Xia,
Anis El Meddeb Hamrouni, Majed Ben Mrad, Alexander Tuan Falk, Claire
Rodriguez-Lafrasse, Chloé Rancoule, et al.

To cite this version:
Alexis Vallard, Sophie Espenel, Jean-Baptiste Guy, Peng Diao, Yaoxiong Xia, et al.. Targeting stem cells by radiation: From the biological angle to clinical aspects. World journal of stem cells, 2016, 8 (8), pp.243-250. <10.4252/WJSC.v8.i8.243>. <hal-01375903>

HAL Id: hal-01375903
https://hal.archives-ouvertes.fr/hal-01375903
Submitted on 3 Oct 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Targeting stem cells by radiation: From the biological angle to clinical aspects

Alexis Vallard, Sophie Espenel, Jean-Baptiste Guy, Peng Diao, Yaoxiong Xia, Anis El Meddeb Hamrouni, Majed Ben Mrad, Alexander Tuan Falk, Claire Rodriguez-Lafrasse, Chloé Rancoule, Nicolas Magné

Abstract

Radiotherapy is a cornerstone of anticancer treatment. However in spite of technical evolutions, important rates of failure and of toxicity are still reported. Although numerous pre-clinical data have been published, we address the subject of radiotherapy-stem cells interaction from the clinical efficacy and toxicity perspective. On one side, cancer stem cells (CSCs) have been recently evidenced in most of solid tumor primary locations and are thought to drive radio-resistance phenomena. It is particularly suggested in glioblastoma, where CSCs were showed to be housed in the subventricular zone (SVZ). In recent retrospective studies, the radiation dose to SVZ was identified as an independent factor significantly influencing overall survival. On the other side, healthy tissue stem cells radio-destruction has been recently suggested to cause two of the most quality of life-impacting side effects of radiotherapy, namely memory disorders after brain radiotherapy, and xerostomia after head and neck radiotherapy. Recent publications studying the impact of a radiation dose decrease on healthy brain and salivary stem cells niches suggested significantly reduced long term toxicities. Stem cells comprehension should be a high priority for radiation oncologists, as this particular cell population seems able to widely modulate the efficacy/toxicity ratio of radiotherapy in real life patients.

Key words: Cancer; Neoplastic stem cells; Radiation therapy; Efficacy; Toxicity
INTRODUCTION

Radiotherapy is a cornerstone of anticancer treatments. However, significant levels of toxicity and recurrences are still reported. On the one hand, cancer stem cells have been recently suggested to be the root of radio-resistance, with strong pre-clinical rational. One the other hand, convincing pre-clinical data suggesting the importance of healthy tissue stem cells radiation-induced destruction in long term side effects of radiotherapy surfaced. This article provides an overview of the available literature analyzing from the clinical efficacy and toxicity perspective the interactions between stem cells and radiation. Significant improvement of radiotherapy toxicity/efficacy ratio is suggested.

TARGETING CSC WITH RADIATION: EFFICACY DATA

Clinical outcomes: The glioblastoma model

Glioblastoma is a major model of radioresistance since in spite of a multi modal approach (ideally combing surgery, radiotherapy and chemotherapy), the median overall survival time only reaches 12-15 mo, with most of the recurrences located in the radiation fields. The underlying phenomena leading glioblastoma to radioresistance are still misunderstood but it was suggested in animal pre-clinical models that the genesis of glioblastoma was linked to a loss of tumor suppressor gene in neural stem cells (NSCs)\(^{23}\). NSCs were shown to be physiologically housed in the subventricular zone (SVZ), an area surrounding the lateral ventricles\(^{24-27}\). Therefore, delivering high doses of radiation to niches of “healthy tissue” (i.e., the SVZ) possibly harboring glioblastoma CSCs might allow to concurrently kill stem cells located in the surrounding healthy tissues, and induce serious radiation-caused toxicities. Ideally, radiotherapy should simultaneously destroy CSCs and spare normal tissue stem cells. Several research approaches actually tried to reach this goal with recent publications regarding the CSC pharmacological targeting\(^{10}\), the CSC dosimetric targeting, and the healthy tissue stem cells sparing. Interesting potential pharmacological targets have been recently suggested: Wnt/β-caderines pathway inhibitors are currently under clinical investigation\(^{11}\), with the strong pre-clinical rational that Wnt/β-caderines ex­pression is directly related with radiation-resistance\(^{12}\), de-differentiation, adhesion, and invasion\(^{13}\). Notch-1 (involved in CSC repopulation\(^{14}\), proliferation and radiation-induced apoptosis resistance\(^{15}\)), SHH (involved in metastases\(^{16}\), CSC proliferation, survival, morphogenesis and radiosensitivity\(^{17}\)), JAK/STAT (involved in CSC de-differentiation, apoptosis resistance, and proliferation\(^{19}\)) and PI-3 kinase/Akt (involved in CSC survival after radiation\(^{20}\)) are pharmacological targets of interest, with inhibitors that are currently tested in pre-clinical studies. Hypoxia is also a major topic of interest, since CSCs are thought to be located in hypoxic niches. In pre-clinical studies, decreasing CSC hypoxia resulted in reduced CSCs self-renewing and multiplication\(^{20,21}\). The pharmacological targeting of tumor and vascular stroma (using PDGF inhibitors) seems therefore promising, with the in vitro radio-sensitisation of CSCs that were initially radio-resistant\(^{22}\). Contrary to pharmacological targeting, the CSC “dosimetric targeting” (i.e., directly targeting stem cells by radiation) is still at its early stages. However, most of the publications consist in clinical studies with already promising outcomes. The sparing of organs at risk stem cells is also a hot topic, since healthy tissue stem cell death was suggested to be directly related to side effects widely impacting patients’ quality of life, occurring after both curative and palliative radiotherapy. The present article’s objective is to address the radiotherapy/stem cells topic from the clinical efficacy and perspective.
Tumorigenesis initiation.

Figure 1 Cancer stem cells main biological characteristics. A: Self-renewal/endless proliferation; B: Giving birth to a high number of progenitor parental cells; C: Tumorigenesis initiation.

overcome its radioresistance. This hypothesis was tested in 2010 by Evers et al.\cite{28}. Data of 55 patients treated for a glioblastoma between 2003 and 2009 in California, United States, were retrospectively reviewed. Dosimetric data of radiotherapy were analyzed in order to estimate the dose delivered to the supposed CSC niches (i.e., the SVZ), and correlate it with patient global outcomes. Only patients with histopathologically diagnosed anaplastic glioma (grade 3) or glioblastoma (grade 4), with at least 1 mo of follow-up, and who completed the whole planned radiotherapy were included. SVZ was defined based on previous publications, and doses to the volumes of interest could be a posteriori calculated. The authors estimated that the median dose received by the bilateral SVZ was 43 Gy. They then divided the population into a "low dose group" (receiving less than the median dose, \(n = 27\)) and a "high dose group" (receiving more than the median dose, \(n = 28\)). The two groups were well balanced on all essential prognosis factors (RPA classification, age, Karnofsky performance scale), but one. Complete resection was less achieved in the "high dose" group (\(n = 6, 21\%\)) than in the "low dose" group (\(n = 16, 59\%\)). The mean dose received by bilateral SVZ was 50 Gy ± 2 Gy for the "high dose group" and 27 Gy ± 5 Gy for the "low dose group". The median progression free survival (PFS, defined as the time between radiotherapy completion and glioblastoma recurrence) was 15 mo for the "high dose group" and 7.2 mo for the "low dose group". This difference was statistically significant (\(P = 0.03\)). Hazard ratio concerning glioblastoma progression was significantly decreased for the "high dose" group (HR = 0.74, 95%CI: 0.567-0.951, \(P = 0.0019\)). All other statistical analyses comparing important characteristics could not evidence significant differences, particularly regarding the total dose (\(P = 0.83\)), highlighting the high degree of glioblastoma’s radioresistance due to CSCs\cite{29}. No correlation was shown between the total dose and dose to SVZ, since SVZ was most of the time outside of the clinical target volume. Therefore, doses per fraction on the SVZ were limited (1.36 Gy CI: 1.2-1.5). The fact that low doses of radiation could result in an increased radio-sensitivity has already been described in glioblastoma\cite{30,31}, but not in CSCs\cite{32}. The underlying biological phenomenon is hypothesized to be the non-detection of DNA damages in case of small doses per fractions, while the CSC radio-resistance is supposedly linked with the over-expression of DNA damage checkpoints\cite{33}. However, CSC high sensitivity to low doses must be studied in prospective clinical studies. Interestingly, when statistical analyses were performed regarding the doses received by the ipsilateral periventricular zone only, no significant difference could be evidenced. Linked with the observation that glioblastoma cells can widely migrate within the healthy brain tissue, causing frequent contralateral recurrences\cite{34}, it was hypothesized that ipsilateral CSCs could take shelter in contralateral CSC niches. Targeting radio-resistant CSC might therefore be more efficient if all the possible CSC harbors are damaged, but this hypothesis is still to be demonstrated. In 2012, Gupta et al.\cite{35} published outcomes of 40 glioblastoma patients treated between 2008 and 2010 at the Tata Memorial Centre, India. All patients were treated for histologically proven glioblastoma using standard treatment. Dosimetric data were retrospectively reviewed, and doses to SVZ were a posteriori calculated and linked with global outcomes. Median dose to bilateral SVZ was 56.2 Gy, and patients were divided as previously described into a "high dose group" (\(n = 20\), mean dose to ipsilateral, contralateral and bilateral SVZ of 60.1 Gy, 59.9 Gy and 60 Gy respectively) and a "low dose group" (\(n = 20\), mean dose to ipsilateral, contralateral and bilateral SVZ of 57.5 Gy, 47.4 Gy and 52.5 Gy respectively). Most of known prognosis factors were unfavorably distributed in the "high dose group" vs "low dose group": Patients were older (55 yo vs 46 yo), with higher RPA class (85% of class IV vs 55%), with less frequent extensive resection (50% vs 70%), and with more frequent MGMT methylation (55% vs 40%). At a median follow-up of 15 mo, 25 out of the 40 patients experienced progression, with 21 deaths. Age and RPA class (well known prognosis factors) were significantly linked with survival in univariate analysis, as well as the dose to contralateral SVZ (\(P = 0.05\)). A Kaplan-meyer
analysis showed significantly increased overall survival ($P = 0.05$) and progression free survival ($P = 0.02$) for patients with the highest doses to contralateral SVZ. In multivariate analysis, RPA class, Karnofsky performance status and dose to ipsilateral SVZ were identified as independent prognosis factors of overall survival (HR = 0.87, 95%CI: 0.77-0.98, $P = 0.025$). These results corroborate the efficacy of targeting CSCs by radiation in glioblastoma. However, the ideal target (ipsilateral or contralateral SVZ) and the dose threshold (43 Gy? 50 Gy?) are still to be clarified. The brain model is certainly one of the most interesting models for the CSC dosimetric targeting: Due to its anatomical conception, CSC niches are distinct from differentiated cells, making the result of a precisely delivered radiotherapy easier to interpret.

**Properly imaging CSC through hypoxia: A necessary condition for an efficient radiotherapy?**

These two publications also reflect the need for reliable imaging of CSC niches. The recent development of spectroscopy (identifying the specific metabolic profile of glioblastoma CSCs) is certainly a very promising technique that could allow a precise dosimetric targeting of CSCs in the future$^{[36,37]}$. Out of the glioblastoma model, the CSC imaging systems are mainly based on hypoxia$^{[38]}$. Hypoxia is thought to be a cornerstone of radiation resistance since it was clearly proven that the biological effects of conventional radiotherapy (i.e., the DNA damages caused by chain oxidation) are potentiated by oxygen. In case of hypoxia, the efficacy of radiotherapy is *de facto* significantly reduced. It also seems clear that tumor hypoxic niches harbor CSCs (in glioblastoma but also in other solid tumors$^{[39]}$) and therefore represent a target of interest for radiotherapy: The most radioresistant cells are housed in a micro-environment enhancing radioresistance. Imaging the hypoxic niches and targeting them by radiation might be the key to overcome cancers radioresistance since higher doses could induce the destruction and the re-oxygenation of these niches, initiating a virtuous cycle. The challenge of properly imaging hypoxia is still ongoing. Efficient nitroimidazole-based tracers were developed during the past 30 years, based on the fact that hypoxia induces a transformation of nitro-imidazole intermediates into alkylation agents that bind to cell component$^{[40]}$. These elements could be then coupled with positron emitting radionuclides ($^{18}$F, $^{64}$Cu, $^{68}$Cu) in order to be detected by positron emission tomography (PET) imaging devices. ($^{18}$F) Fluoromisonidazole and ($^{18}$F) 1-(5-fluoro-5-deoxy-$\alpha$-D-arabinofuranosyl)-2-nitroimidazole were validated (regarding specificity) by invasive gold standard methods and can be now clinically used. However, sensitivity is still limited due to low tumor-to-plasma ratios and poor spatial resolution of PET imaging systems$^{[38]}$. Techniques based on magnetic resonance imaging (MRI) have been developed, resolving the issue of spatial resolution (Blood oxygen dependent MRI imaging, Mapping of Oxygen by Imaging Lipid Relaxation Enhancement, and Dynamic-Contrast-Enhanced MRI), but sensitivity issues remained$^{[38]}$. Moreover, recent data suggested that CSC were not necessarily located in the most hypoxic areas$^{[41]}$, making multi-modal imaging methods absolutely needed (coupled PET-MRI, or imaging techniques detecting CSC surface marker). In this field, nanoparticles are very promising theragnostic tools, since they can be used both as MRI contrast agents, and as radiotherapy targets$^{[42,43]}$. Finally, the ideal solution might be a radiotherapy technique capable of destroying as well CSC as differentiated cancer cells. Hadrontherapy (carbon or proton-based radiotherapy) seems to fulfill these criteria, showing in vitro the ability to kill with the same efficacy CSCs and conventional cancer cells, thanks to the absence of oxygen effect$^{[44]}$. However, the high cost of this technique might be a clear drawback to its routine application. Moreover, radio-resistance phenomena have been very recently described in vitro and need to be fully investigated to evaluate their possible clinical impact$^{[45]}$.

**SPARING NORMAL STEM CELLS DURING RADIOThERAPY: TOXICITY DATA**

**Clinical outcomes: The whole brain radiotherapy model**

Memory disorders are a well known long term side effect of whole brain radiotherapy (WBRT), performed in case of multiple brain metastases. Radio-damaged neural stem cells (NSCs) located in the subgranular zone of the hippocampal dentate gyrus$^{[46]}$ have been hypothesized to cause the reported cognitive decline following WBRT$^{[47]}$. Thanks to the development of the intensity modulated radiotherapy (IMRT), Gondi et al$^{[48]}$ showed the feasibility of a WBRT avoiding (i.e., reducing the delivered dose of $\geq 80\%$) to the hippocampal NSC niches, without impairing the quality of coverage of the remaining brain. IMRT offers the possibility to spare areas that could not be spared with conventional radiotherapy indeed, thanks to highly conformal dose painting (Figure 2). Gondi et al$^{[49]}$ published in 2014 the outcomes of an international single-arm phase II trial, comparing the results of a WBRT sparing hippocampal NSCs with the results of a 2003 phase III trial using conventional WBRT for brain metastasis. Patients treated using WBRT for solid tumor brain metastasis were assessed for standardized cognitive assessments (Hopkins Verbal Learning Test-Revised Delayed Recall (HVLT-R DR)) at baseline, 2-, 4- and 6-month follow-up, with a primary endpoint being the HVLT-R DR at 4 mo. At 4 mo, the mean relative decline in HVLT-R DR score from baseline was of 30% in the 2003 control trial. In the experimental trial, hippocampal NSC niches definition was standardized and based on MRI fusion with planning computed tomography-scan. Standard (and similar to the control trial) fractionation scheme was delivered, with 30 Gy in 10 fractions. Doses were limited to 9 Gy to the entire hippocampus, with a maximum focal dose of 16 Gy. Between 2011 and 2012, 113 patients were included, with 42 patients being
analyzable for the primary endpoint. At 4 mo, the mean relative HVLT-R DR impairment was significantly lower in the population who experienced the hippocampal NSC protection compared to the population who did not (7% vs 30%, \( P < 0.001 \)). Interestingly, if most of patients experienced intracranial progression, with a mean overall survival of 6.8 mo, only 4.5% of patients developed intra-hippocampal progression. The authors concluded that the avoidance of hippocampal NSC was significantly related to memory preservation, bringing a direct clinical evidence that hippocampal NSC niche was implicated in the pathophysiology of radiotherapy-induced memory decline. Of course, the main limitation of this article is the absence of direct control group, but phase III trials have been approved and will clarify the place and efficacy of NSC avoidance during WBRT.

**Clinical outcomes: The head and neck radiotherapy model**

Xerostomia is one of the most quality of life-impacting late side effects of head and neck radiotherapy. Oral dryness frequently ruins patients’ everyday life inducing ulcerations, speech, taste and swallowing difficulties. Even with modern radiotherapy techniques minimizing mean dose to salivary glands, important rates of mucosal complications (15% to 40% of treated patients) are still reported\(^ {50,51} \). It was clearly demonstrated that the xerostomia was linked with the irradiation of salivary glands, because of the high radiosensitivity of stem cells niches located in the salivary glands\(^ {50,52,53} \). Xerostomia seemed to be proportionally linked with the dose delivered to salivary gland stems cells niches, determining the quantity of post radiotherapy viable salivary stem cells\(^ {52,54} \). However, the clinically relevant threshold dose of radiotherapy damaging stem cells is still undetermined and only techniques delivering doses as low as reasonably achievable to parotid stem cells-rich regions were tested. Moreover, the exact location of these areas is still debated, the strongest hypothesis being they could be located in the larger excretory ducts\(^ {18} \). Based on animal models, van Luik et al\(^ {55} \) suggested that the centre of the parotid (containing the major ducts) was certainly rich in stem cells, since its restricted irradiation leaded to long term saliva production collapse. This hypothesis was recently tested in humans\(^ {55} \). Salivary and dosimetric data of 74 patients treated for a head and neck cancer without salivary gland involvement were retrospectively reviewed. Spatial dose distribution inside the parotid could be correlated to salivary flows 1 year after radiotherapy completion (with a dose-dependent effect relationship), defining a stem cell region located near the dorsal edge of the mandible, at the occurrence of the first branching of Stensen’s duct, in concordance with animal stem cells locations. Doses delivered to this area were more predictive of salivary flow than (routinely used) parotid mean dose. Moreover, after radiotherapy, only cells provided by biopsies of these zones could be grown *in vitro*. A feasibility study was performed in 22 patients, showing that the preservation of the parotid stem cell niche seemed feasible with IMRT, even in case of impossible avoidance of the whole parotid. Other areas of parotid have been suggested to house stem cells capable of salivary long-term regeneration. It was suggested in one retrospective cohort derived from an important phase III study that sparing the superficial lobe of the two parotid glands could induce a better salivary preservation than complete contralateral parotid gland sparing\(^ {57} \). These data need to be validated in larger patient cohorts, but might be a significant progress in order to limit radiation-induced xerostomia. The main limitation of these articles (out of their retrospective nature) is that the link between salivary flow and xerostomia is still unclear: The major salivary glands (parotid glands, submandibular glands and sublingual glands) produce 90% of saliva, but minor salivary glands (thousands of small glands located in the oral cavity) secrete the major quantity of mucin, the saliva lubricating agent. Mucin is also secreted for a small account by submandibular glands and sublingual glands. Therefore, only shielding parotids stem cells might insufficient to guarantee the restoration of good quality saliva after radiotherapy. Pre-clinical and clinical data are certainly needed concerning the radio-sensitivity and the location of stem cells in the submandibular and minor salivary glands. Currently, no reliable biological or
imaging markers have been validated to precisely locate salivary stem cells, making progresses difficult to be made.

CONCLUSION

If the interaction between radiotherapy and CSCs is an en vogue topic, targeting CSC by radiation is at its early stage of development. Combining radiotherapy with biological drugs targeting CSC could be an efficient mean to overcome local and metastatic recurrences, with various agents that are currently tested based on solid pre-clinical rationales. But directly targeting CSC using radiation is also a promising anticancer therapy with already interesting clinical results. The evolution of modern techniques of radiotherapy might widely depend on the imaging progresses in term of sensitivity. In order to increase the therapeutic index of radiotherapy, sparing stem cells of healthy tissue is also a major topic of interest since significant improvements regarding quality of life-impacting side effects following radiotherapy can be achieved. More than ever, prospective trials with solid methodologies are needed to confirm or infirm the suggested trends. Finally, both cancer and normal tissue stem cells seem to be central elements modulating the toxicity and the efficacy of radiotherapy. A better comprehension of stem cells location and their intrinsic radio-sensitivity is crucial, and permanent return trips between preclinical and clinical data are mandatory.

REFERENCES


Vallard A et al. Radiotherapy and stem cells: Clinical aspects


P- Reviewer: Kita K, Liu J, Liu L, Nechifor G  
S- Editor: Ji FF  
L- Editor: A  
E- Editor: Li D